Get started
Author

Marco Soro

Observed names: M Soro, M. Soro
ORCID: 0000-0002-7958-818X
Observed ORCID: 0000-0002-7958-818X
OpenAlex ID: A5110690209
Cost of poor adherence to anti-hypertensive therapy in five European countries
2014 · F. S. Mennini, A. Marcellusi, et al. · The European Journal of Health Economics · 225
Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
2021 · Yang Xu, Marie Evans, et al. · Clinical Kidney Journal · 73
PDF
Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension
2015 · Pedro Marques da Silva, Uwe Haag, et al. · Health and Quality of Life Outcomes · 26
PDF
Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries
2019 · A. Marcellusi, R. Viti, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 19
PDF
Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial
2024 · James Fotheringham, Julian Guest, et al. · Patient · 18
PDF
Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population
2023 · Simona Barbuto, Valentina Perrone, et al. · Nutrients · 17
PDF
High prevalence of diabetes‐specific autoimmunity in first‐degree relatives of Sardinian patients with type 1 diabetes
2016 · M. Incani, C. Serafini, et al. · Diabetes/Metabolism Research and Reviews · 17
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis
2023 · Praveen Thokala, Pann Ei Hnynn Si, et al. · PharmacoEconomics · 12
PDF
Organisational and financial consequences of the early discharge of patients treated for acute bacterial skin and skin structure infection and osteomyelitis in infectious disease departments in Greece, Italy and Spain: a scenario analysis
2019 · Umberto Restelli, Marzia Bonfanti, et al. · BMJ Open · 11
PDF
Health Care Costs in Patients with and without Secondary Hyperparathyroidism in Spain
2021 · Enrique Alonso-Perez, Carles Forné, et al. · Advances in Therapy · 6
Cost effectiveness of difelikefalin for the treatment of patients with chronic kidney disease-associated pruritus undergoing hemodialysis in Italy
2024 · Lucio Manenti, Andrea Marcellusi, et al. · Journal of Nephrology · 2
PDF
POSC312 A Methodological Approach to Assess the Economic Value of Difelikefalin to Treat Chronic Kidney Disease Associated Pruritus (CKD-AP)
2022 · M Soro, P Thokala, et al. · Value in Health · 1
P0891meta-analysis of Nutritional Vitamin D for the Treatment of Secondary Hyperparathyroidism in Patients With Non-dialysis Chronic Kidney Disease
2020 · Joel Gunnarsson, Rosa Lauppe, et al. · Nephrology Dialysis Transplantation · 1
PDF
Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country
2015 · F. S. Mennini, Andrea Marcellusi, et al. · The European Journal of Health Economics · 1
Health-Related Quality Of Life Impact Of Triple Combinations Of Olmesartan Medoxomil, Amlodipine Besylate And Hydrochlorothiazide In Subjects With Hypertension
2014 · U. Haag, J.F. Guest, et al. · Value in Health · 1
PDF
Epidemiologia della chetoacidosi diabetica in Italia
2014 · Valentino Cherubini, Rosaria Gesuita, et al. · ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) · 1
Hospital Burden and Care Pathways of ANCA-Associated Vasculitis in Italy: A Focus on Clinical, Economic, and Geographic Dimensions
2026 · Helen Banks, Giovanni Fattore, et al. · PharmacoEconomics - Open
PDF
Real-World Effect of Difelikefalin on Missed Dialysis Treatment Burden in Adult Patients on Hemodialysis
2026 · Tejas Desai, Marco Soro, et al. · Journal of the American Society of Nephrology
Difelikefalin Treatment in Chronic Kidney Disease-Associated Pruritus: Modelling Infection-Related Hospitalisation Cost Offsets Using Trial and Real-World Data Across Seven European Countries
2026 · Annabel Rayner, James Fotheringham, et al. · Advances in Therapy
PDF
Management of hyperkalaemia in the Italian clinical practice: impact of diverse potassium binders on outcomes and costs in patients with chronic kidney disease and heart failure
2026 · Alessandro Fucili, Valentina Perrone, et al. · International Urology and Nephrology
PDF
Hospitalization and Emergency Department Costs in Patiromer and Sodium Zirconium Cyclosilicate Users
2026 · Nihar R. Desai, Charuhas Thakar, et al. · Kidney360
#2911 Projections of infection-related cost savings associated with treating CKD associated pruritus (CKD-aP) with difelikefalin in five European countries through the combination of clinical trial data and real-world evidence
2025 · Annabel Rayner, James Fotheringham, et al. · Nephrology Dialysis Transplantation
PDF
CKD-Associated Pruritus is Associated with Greater Use of Antidepressants and Anti-pruritus Medications
2025 · Jasmine Ion Titapiccolo, Luca Neri, et al. · Advances in Therapy
PDF
EE631 Cost-Effectiveness of Difelikefalin Compared to Best Supportive Care for Treatment of Chronic Kidney Disease-Associated Pruritus in Australia
2024 · D Jackson, M Ratkovic, et al. · Value in Health
PDF
PCR98 Reduced Dialysis Adherence and Greater Medication Use Associated with Increased Itch Severity
2023 · J. Ion Titapiccolo, M. Soro, et al. · Value in Health
Works count: 34
Citation count: 431
H-index: 9
I10-index: 9
Year
Topic
Type